Ask AI
PsO Treatment Decision Tool
Expert Guidance on Personalized Management for Individuals With Moderate to Severe Psoriasis and Associated Comorbidities

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: July 21, 2025

About This Tool & Disclaimer

Expert Guidance on Personalized Management for Individuals With Moderate to Severe Psoriasis and Associated Comorbidities 

Clinical Care Options, LLC, is grateful to Benjamin Ungar, MD; Tina Bhutani, MD, MAS, FAAD; and Linda Stein Gold, MD., who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in July 2025 and reflects the guidelines available at that time.

The goal of the tool is to educate clinicians on making optimal management choices for optimizing the management of patients with moderate to severe psoriasis.

A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include inflammatory bowel disease, obesity, hypertension, heart disease and malignancy and other comorbidities.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with moderate to severe psoriasis. Other considerations that are not included in this tool, such as the presence psoriatic arthritis and spondyloarthritis and any concurrent medications, should also be considered, when appropriate for making management decisions.

This tool assumes we have a “standard” patient with moderate to severe psoriasis but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display Joint American Academy of Dermatology (AAD)-National Psoriasis Foundation (NPF) guideline-based recommendations for that specific patient case.

For additional information on best practices in the management of patients with moderate to severe psoriasis, please see our online module titled, “Personalized Care For Individuals With Moderate to Severe Psoriasis and Associated Comorbidities" authored by Benjamin Ungar, MD; Tina Bhutani, MD, MAS, FAAD; Linda Stein Gold, MD.

This program is supported by an educational grant from Lilly and Sun Pharmaceutical Industries, Inc.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Benjamin Ungar, MD, has disclosed that he has received funds for research support from Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, UCB; researcher: Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, Sanofi.​

Tina Bhutani, MAS, FAAD, has disclosed that he has received funds for research support from Amgen, Castle, CorEvitas, Novartis, Pfizer, Regeneron; consultant/advisor/speaker: AbbVie, Arcutis, Aslan, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun, Takeda, UCB. ​

Linda Stein Gold, MD, has disclosed that he has received funds for research support from AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Janssen, Lilly, UCB.

© 2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance on Personalized Management for Individuals With Moderate to Severe Psoriasis and Associated Comorbidities” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate dermatologists nurse practitioners, and physician associates who are involved in the care of patients with moderate and severe psoriasis for monitoring or treating individuals with moderate to severe psoriasis. The information provided is based on the Joint American Academy of Dermatology (AAD)-National Psoriasis Foundation (NPF) guideline recommendations and expert guidance of Benjamin Ungar, MD; Tina Bhutani, MD, MAS, FAAD; and Linda Stein Gold, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Guidance on Personalized Management for Individuals With Moderate to Severe Psoriasis and Associated Comorbidities” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2025 Clinical Care Options, LLC. All rights reserved.

Program Content